title: A bioequivalence study of levothyroxine tablets versus an oral levothyroxine solution in healthy volunteers.
abstract: Probably for genetic reasons a substantial part of the Greek population requires Levothyroxine treatment. Since commercially available Levothyroxine was first marketed, the manufacture and storage of the drug in tablet form has been complicated and difficult; and as cases of therapeutic failure have frequently been reported following treatment with this medicinal agent, quality control is an essential factor. Due to the unreliability of Levothyroxine-based commercial products, in the present study we decided to follow the Food and Drug Administration (FDA) guidelines*, and use a Levothyroxine solution as reference product. The bioavailability of the Levothyroxine sodium tablet formulation THYROHORMONE/Ni-The Ltd (0.2 mg/tab) and that of a reference oral solution (0.3 mg/100 ml) under fasting conditions were compared in an open, randomized, single-dose two-way crossover study. Twenty four healthy Caucasian volunteers (M/F=15/9, mean age=32.9+/-7.4yr) participated in the study. Bioavailability was assessed by pharmacokinetic parameters such as the area under plasma concentration-time curve from time zero up to the measurable last time point (AUC(last)) and the maximum plasma concentration (Cmax). Heparinized venous blood samples were collected pre-dose and up to a 48-hour period post-dose. Levothyroxine sodium in plasma samples was assayed by a validated electrochemiluninescent immunoassay technique. Statistical analysis showed that the post-dose thyrotropin-stimulating hormone (TSH) levels decreased significantly (p<0.05). Regarding Levothyroxine (T4), the point estimate of the test formulation to the reference formulation ratios (T/R) for AUC(last) and Cmax was 0.92 with 90% confidence limits (0.90, 0.94) and 0.93 with 90% confidence limits (0.91, 0.94), respectively. Regarding triiodo-L-thyronine (T3), the point estimate for the T/R ratios of AUC(last) and Cmax was 0.92 with 90% confidence limits (0.90, 0.95) and 0.94 with 90% confidence limits (0.92, 0.95), respectively. The 90% confidence limits for the pharmacokinetic parameters AUC(last) and Cmax lie within the acceptance limits for bioequivalence (0.80, 1.25), for both T3 and T4.
authors.affiliation: Skylab-Med Laboratories, Halandri, Athens, Greece.
authors.forename: N
authors.initials: N
authors.lastname: Yannovits
authors.forename: E
authors.initials: E
authors.lastname: Zintzaras
authors.forename: A
authors.initials: A
authors.lastname: Pouli
authors.forename: G
authors.initials: G
authors.lastname: Koukoulis
authors.forename: S
authors.initials: S
authors.lastname: Lyberi
authors.forename: E
authors.initials: E
authors.lastname: Savari
authors.forename: S
authors.initials: S
authors.lastname: Potamianos
authors.forename: F
authors.initials: F
authors.lastname: Triposkiadis
authors.forename: I
authors.initials: I
authors.lastname: Stefanidis
authors.forename: E
authors.initials: E
authors.lastname: Zartaloudis
authors.forename: A
authors.initials: A
authors.lastname: Benakis
mesh_terms: D000284:Administration, Oral; D000328:Adult; D006801:Humans; D007118:Immunoassay / Q000379:methods; D008875:Middle Aged; D015203:Reproducibility of Results; D012996:Solutions; D013607:Tablets; D013810:Therapeutic Equivalency; D013972:Thyrotropin / Q000097:blood; D013974:Thyroxine / Q000008:administration & dosage / Q000097:blood / Q000493:pharmacokinetics*; D014284:Triiodothyronine / Q000097:blood
chemical_list: D012996:Solutions; D013607:Tablets; D014284:Triiodothyronine; D013972:Thyrotropin; D013974:Thyroxine